|
|
|
|
|
|
|
|
news
Genetic testing company Myriad Genetics, the defendant in a landmark Supreme Court case over gene patents, is back in the spotlight — this time, for withholding genetic data from patients.
Myriad held patents on the BRCA1 and BRCA2 genes until 2013, and tested more than 1 million patients for variations in those genes that might increase a person’s risk of breast, ovarian, prostate, and other cancers.
Though Myriad no longer holds the patents on
those genes, it still holds patients’ data, and has been resistant to
sharing it with researchers or public databases....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.